Moreau, PhilippeChari, AjaiOriol, AlbertMartinez-Lopez, JoaquinHaenel, MathiasTouzeau, CyrilleAilawadhi, SikanderBesemer, Brittade la Rubia Comos, JavierEncinas, CristinaMateos, Maria-VictoriaSalwender, HansRodriguez-Otero, PaulaHulin, CyrilleKarlin, LionelSureda, AnnaBargay Lleonart, JoanBenboubker, LotfiRosiñol, LauraTarantolo, StefanoTerebelo, HowardYang, ShiyiWang, Jing JingNnane, IvoQi, MingKosh, MicheleDelioukina, MariaGoldschmidt, HartmutMoreau, PhilippeChari, AjaiOriol, AlbertMartinez-Lopez, JoaquinHaenel, MathiasTouzeau, CyrilleAilawadhi, SikanderBesemer, Brittade la Rubia Comos, JavierEncinas, CristinaMateos, Maria-VictoriaSalwender, HansRodriguez-Otero, PaulaHulin, CyrilleKarlin, LionelSureda, AnnaBargay Lleonart, JoanBenboubker, LotfiRosiñol, LauraTarantolo, StefanoTerebelo, HowardYang, ShiyiWang, Jing JingNnane, IvoQi, MingKosh, MicheleDelioukina, MariaGoldschmidt, Hartmut2024-10-092024-10-092023-03-07Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, et al. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33.https://hdl.handle.net/20.500.13003/18923https://hdl.handle.net/20.500.12105/23626enghttp://creativecommons.org/licenses/by/4.0/Multiple MyelomaAntibodies, MonoclonalHumansNeoplasms, Plasma CellDexamethasoneletter to the editorAtribución 4.0 Internacional368824091313310.1038/s41408-023-00805-x2044-5385Blood cancer journalopen accessDexametasonaHumanosNeoplasias de Células PlasmáticasMieloma MúltipleAnticuerpos Monoclonales2-s2.0-85149595607950825100001L2021978120